Citadel Advisors
CVKD icon

Citadel Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

Citadel Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,864
Closed -$274K – 12851
2025
Q3 		$274K Buy
+19,864
New +$246K ﹤0.01% 10574
2024
Q3 		– Sell
-3,636
Closed -$25.6K – 14365
2024
Q2 		$25.6K Sell
3,636
-87
-2% -$602 ﹤0.01% 12421
2024
Q1 		$34.1K Buy
+3,723
New +$47.2K ﹤0.01% 12562
2023
Q4 		– Sell
-1,941
Closed -$19.8K – 14388
2023
Q3 		$19.8K Buy
+1,941
New +$27.6K ﹤0.01% 12637

Other funds holding CVKD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's CVKD Position: Q4 2025 in Review

Citadel Advisors sold out of Cadrenal Therapeutics (CVKD) in Q4 2025, closing a stake of 19,864 shares — an estimated $274K sold.

Citadel Advisors first reported a position in CVKD in Q3 2023 and held it in 4 quarters. The position peaked at $274K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q4 2025.

  • Citadel Advisors reported no remaining Cadrenal Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 19,864 Cadrenal Therapeutics shares in Q4 2025, an estimated $274K.
  • Citadel Advisors first reported a position in Cadrenal Therapeutics in Q3 2023 and held it in 4 quarters.
  • Citadel Advisors's Cadrenal Therapeutics position peaked at $274K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.